Since the patient’s cost is effectively zero in the Medicaid population, getting patients engaged in their care often requires some ingenuity to figure out what the patient needs in order to be motivated in their own health, said Matt Salo.
“Is child care your biggest issue?” Salo asked. “Well let’s figure out: if you can go to the highest quality, lowest price provider, maybe we can kick in some child care subsidy or something like that. You can be creative.”
Figuring those things out is complicated, but can be done, and it aligns with the way insurance is changing to embrace social determinants of health, he added.
Leah Binder agreed that it is important to create incentives to creatively build benefits designs based on what the patients actually value. “But our healthcare system has no tradition at all of caring at all about what patients think,” she said.
And when the system does try to define quality, it’s usually in a scientific way that considers what is high quality or what the most people think. But the industry needs to start understanding the nuances between how different people view value, Binder said.
In the end, this will all come down to research, Austin Frakt, PhD, said. The data on these innovative models need to be available and accessible in order for independent researchers to know the effects of these programs.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
American Advocacy and Action for Minority Health in 2025
April 4th 2025Accessing equitable health care is an ongoing struggle in the US for minority communities due to historical pretexts with new setbacks surfacing as recent administrative changes emerge, highlighting the urgent need for continued advocacy during National Minority Health Month.
Read More
Radiation Bridging Therapy Boosts CAR T Outcomes in R/R LBCL
April 3rd 2025In this comparative analysis, patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) received bridging therapy via radiation or systemic treatment while their chimeric antigen receptor T-cell therapy (CAR T) was being manufactured.
Read More